Search research articles
Contact Us
Filters
Showing results (151-160 of 233) with videos related to
Page
of 24
Sort By:
Analytical and Quantitative Cytology and Histology
|
August 12, 2010
Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target
Mario Scartozzi, Italo Bearzi, Alessandra Mandolesi, et al.
Journal of Cancer Research and Clinical Oncology
|
February 20, 2017
Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study
Maria Rita Migliorino, Antonio Santo, Giampiero Romano, et al.
Clinical Colorectal Cancer
|
April 2, 2018
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study
Alessandro Pastorino, Maria Di Bartolomeo, Evaristo Maiello, et al.
Scientific Reports
|
April 6, 2017
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis
Riccardo Giampieri, Michela Del Prete, Tiziana Prochilo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2017
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients
Stefano Cascinu, Gerardo Rosati, Guglielmo Nasti, et al.
Cancers
|
September 3, 2020
A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic
Alberto Zaniboni, Michele Ghidini, Francesco Grossi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2024
Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer
Tiziana Pressiani, Rita Balsano, Laura Giordano, et al.
Clinical Breast Cancer
|
December 21, 2020
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study
Nicla La Verde, Elena Collovà, Livio Blasi, et al.
Clinical Colorectal Cancer
|
March 9, 2019
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
Lorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio, et al.
British Journal of Cancer
|
September 20, 2017
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial
Riccardo Giampieri, Marco Puzzoni, Bruno Daniele, et al.
Page
of 24
Search research articles
Search
Showing results (151-160 of 233) with videos related to
Sort By:
Page
of 24
Analytical and Quantitative Cytology and Histology
|
August 12, 2010
Epidermal growth factor receptor gene promoter methylation in primary colorectal tumors and corresponding metastatic sites: a new perspective for an "old" therapeutic target
Mario Scartozzi, Italo Bearzi, Alessandra Mandolesi, et al.
Journal of Cancer Research and Clinical Oncology
|
February 20, 2017
Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study
Maria Rita Migliorino, Antonio Santo, Giampiero Romano, et al.
Clinical Colorectal Cancer
|
April 2, 2018
Aflibercept Plus FOLFIRI in the Real-life Setting: Safety and Quality of Life Data From the Italian Patient Cohort of the Aflibercept Safety and Quality-of-Life Program Study
Alessandro Pastorino, Maria Di Bartolomeo, Evaristo Maiello, et al.
Scientific Reports
|
April 6, 2017
Off-target effects and clinical outcome in metastatic colorectal cancer patients receiving regorafenib: The TRIBUTE analysis
Riccardo Giampieri, Michela Del Prete, Tiziana Prochilo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 24, 2017
Treatment sequence with either irinotecan/cetuximab followed by FOLFOX-4 or the reverse strategy in metastatic colorectal cancer patients progressing after first-line FOLFIRI/bevacizumab: An Italian Group for the Study of Gastrointestinal Cancer phase III, randomised trial comparing two sequences of therapy in colorectal metastatic patients
Stefano Cascinu, Gerardo Rosati, Guglielmo Nasti, et al.
Cancers
|
September 3, 2020
A Review of Clinical Practice Guidelines and Treatment Recommendations for Cancer Care in the COVID-19 Pandemic
Alberto Zaniboni, Michele Ghidini, Francesco Grossi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2024
Multicenter phase I/II trial of gemcitabine, oxaliplatin and nab-paclitaxel as first-line treatment for patients with advanced biliary tract cancer
Tiziana Pressiani, Rita Balsano, Laura Giordano, et al.
Clinical Breast Cancer
|
December 21, 2020
Overall Survival in Metastatic Breast Cancer Patients in the Third Millennium: Results of the COSMO Study
Nicla La Verde, Elena Collovà, Livio Blasi, et al.
Clinical Colorectal Cancer
|
March 9, 2019
Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
Lorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio, et al.
British Journal of Cancer
|
September 20, 2017
First-line FOLFIRI and bevacizumab in patients with advanced colorectal cancer prospectively stratified according to serum LDH: final results of the GISCAD (Italian Group for the Study of Digestive Tract Cancers) CENTRAL (ColorEctalavastiNTRiAlLdh) trial
Riccardo Giampieri, Marco Puzzoni, Bruno Daniele, et al.
Page
of 24